4.6 Article

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naive, cisplatin-ineligible urothelial cancer

期刊

ESMO OPEN
卷 8, 期 3, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.esmoop.2023.101173

关键词

immune checkpoint inhibitor; avelumab plus axitinib; urothelial carcinoma; non-small-cell lung cancer

类别

向作者/读者索取更多资源

This study aimed to investigate the clinical outcomes of avelumab plus axitinib in advanced NSCLC or UC patients. The results showed that in NSCLC patients, objective response rate (ORR) was superior to anti-PD-L1 or anti-PD-1 monotherapy, regardless of PD-L1 status. In UC patients, ORR was lower than expected. Rating: 8 out of 10.
Background: We hypothesized that avelumab plus axitinib could improve clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC) or urothelial carcinoma (UC). Patients and methods: We enrolled previously treated patients with advanced or metastatic NSCLC, or untreated, cisplatin-ineligible patients with advanced or metastatic UC. Patients received avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily. The primary endpoint was objective response rate (ORR). Immunohistochemistry was used to assess programmed death-ligand 1 (PD-L1) expression (SP263 assay) and the presence of CD8+ T cells (clone C8/144B). Tumor mutational burden (TMB) was assessed by whole-exome sequencing. Results: A total of 61 patients were enrolled and treated (NSCLC, n = 41; UC, n = 20); 5 remained on treatment at data cut-off (26 February 2021). The confirmed ORR was 31.7% in the NSCLC cohort and 10.0% in the UC cohort (all partial responses). Antitumor activity was observed irrespective of PD-L1 expression. In exploratory subgroups, ORRs were higher in patients with higher (>median) CD8+ T cells in the tumor. ORRs were higher in patients with lower TMB (median) in the UC cohort. Treatment-related adverse events (TRAEs) occurred in 93.4% of patients, including grade >3 TRAEs in 55.7%. Avelumab exposures with 800 mg Q2W dosing were similar to those observed with 10 mg/kg Q2W dosing. Conclusions: In previously treated patients with advanced/metastatic NSCLC, ORR appeared to be superior to anti-PD-L1 or anti-programmed cell death protein 1 monotherapy, irrespective of PD-L1 status, whereas in untreated, cisplatin-ineligible patients with advanced/metastatic UC, ORR was lower than expected, potentially limited by small patient numbers. Trial registration: Clinicaltrial.gov NCT03472560; https://clinicaltrials.gov/ct2/show/NCT03472560

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据